Physician profile
Jillian Cepeda
NPI 1154708147
$9,491.79
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,095 · 2020: $1,711 · 2021: $1,541 · 2022: $1,607 · 2023: $2,072 · 2024: $466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,529 · Education: $9.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,528.60 |
| Education | $9.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,492.04 | 2019-2023 | |
| Amgen INC. | $1,459.28 | 2019-2024 | Enbrel, Otezla, Prolia |
| Abbvie INC. | $1,409.28 | 2019-2024 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $1,127.13 | 2019-2024 | Tremfya |
| Lilly USA, LLC | $663.68 | 2019-2024 | Taltz |
| Glaxosmithkline, LLC. | $610.25 | 2019-2023 | Benlysta |
| Ucb, INC. | $473.16 | 2019-2024 | Cimzia |
| Radius Health, INC. | $429.93 | 2019-2023 | |
| Pfizer INC. | $420.32 | 2019-2023 | |
| Mallinckrodt Hospital Products INC. | $276.63 | 2020-2024 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $269.32 | 2019-2021 | |
| Aurinia Pharma U.S., INC. | $137.38 | 2021-2024 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $125.13 | 2021-2023 | Saphnelo |
| Horizon Therapeutics Plc | $108.77 | 2020-2023 | Krystexxa |
| Sobi, INC | $84.99 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $83.57 | 2019-2021 | |
| Genzyme Corporation | $73.75 | 2019 | |
| Depuy Synthes Sales INC. | $63.95 | 2019-2021 | |
| Genentech USA, INC. | $57.17 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $35.72 | 2020-2021 | |
| Alvogen INC | $25.96 | 2023 | Teriparatide |
| Fidia Pharma USA INC. | $23.54 | 2021 | |
| Celgene Corporation | $23.38 | 2019 | |
| Eyevance Pharmaceuticals LLC | $17.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jillian Cepeda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.